XNCR Xencor Inc: Enterprise Value-to-Revenue Multiple

Public company logo of xencor.com (XNCR)

Xencor, Inc. (XNCR) generates stable royalties by licensing unique proteins to pharmaceutical behemoths. The company's technological base serves as the intellectual core for creating effective oncology drugs, while its scaling strategy relies on the expansion of clinical trials. The EV/Sales trajectory illustrates the business value-to-revenue dynamics, where 11508.01 determines the latest valuation metric for the asset's market potential.

Company Value to Revenue: Xencor Inc (XNCR) for 11/23/2025 - 11/20/2026

xencor.com - analytical breakdowns and key metrics (XNCR)

- share price and consensus valuation forecast:
Initial company analysis:Xencor, Inc. XNCR
Product sample of Xencor, Inc.

The EV/Sales ratio determines the value of a business, including net debt, relative to its sales volume. By analyzing changes in the EV/Sales ratio, an investor can gauge the extent of asset overvaluation by the market. The current value of 11508.01 reflects the balance between capitalization and actual revenues. For Xencor, Inc. (XNCR), this metric is stabilizing due to steady royalties from platform licensing. Such financial inertia confirms the fundamental reliability of the business model.

Competitor analysis for Xencor, Inc.

IBRX (immunitybio.com) - Company Value to Revenue Ratio|Immunocore Corp (IMCR) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Janux Pharma (JANX)|Company Value to Revenue RCUS|ZYME - Enterprise Value-to-Sales Ratio|Company Value to Revenue TNGX (Tango Pharma)|Enterprise Value-to-Revenue Coefficient IOVA|EV/Sales Multiple IMTX (Immatics)|Business Value to Revenue CMPX|replimune.com - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Lyell Pharma|Innate Pharma S.A. (IPHA) - Enterprise Value-to-Revenue Ratio|Pyxis Oncology Inc. - Business Value to Revenue|CGEN (Compugen Limited) - EV/Sales Multiple|EV/Sales Multiple IO Biotech Inc|Enterprise Value-to-Revenue Ratio Sutro Biopharma (STRO)|INKT: Enterprise Value to Sales Volume|Werewolf Therapeutics, Inc. - Company Value to Revenue|Immix (IMMX) - Enterprise Value-to-Revenue Multiple|ALX Oncology Holdings Inc. - EV/Sales Multiple|CUE - EV/Sales Multiple|PDSB: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Sonnet BioTherapeutics Holdings Inc. (SONN)|MAIA (MAIABiotech.com) - EV/Sales Multiple|Company Value to Revenue Liminatus Pharma (LIMN)|EV/Sales Multiple LVTX|Enterprise Value-to-Revenue Coefficient NXTC|Leap Therapeutics, Inc. - Company Value to Revenue|INTS: Company Value to Revenue Ratio|Sensei Biotherapeutics Inc - EV/Sales Multiple|TOVX: Enterprise Value-to-Revenue Ratio|gritstonebio.com (GRTS) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio KA|Enterprise Value-to-Revenue Ratio NexImmune, Inc.|Company Value to Revenue Ratio TSBX (Turnstone Biologics)|Company Value to Revenue VCNX (Vaccinex, Inc.)|Enterprise Value-to-Revenue Coefficient HARP